Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Fibromyalgia: Doctor Offers Unbiased Overview In New Book
As many as fifteen million American women suffer from a disabling medical condition known as fibromyalgia. In the medical community, sides have been drawn over whether fibromyalgia is a genuine syndrome or a catchall diagnosis based on vague clinical criteria. In The Fibromyalgia Controversy, M. Clement Hall, MD presents an unbiased overview of the fibromyalgia situation today and reviews the most up-to-date opinions and studies on this condition and its surrounding controversy.
generic viagra online
Being Overweight With Heart Risk In Mid Life Followed By Weight Loss Linked To More Illness And Higher Risk Of Death Later
Researchers in Finland who tracked the health of over 1,000 men from middle age into old age found that being overweight and having high risk
News of the day
ACCP Position Paper On Genetic Tests Advertised Directly To The Consumer
Genetic testing services have recently begun to be advertised directly to the patient, and the results of the consumers" response can affect public health, as well as the future adoption of pharmacogenetic/genomic testing, according to a position paper from the American College of Clinical Pharmacology (ACCP) to be published in the August 2009 issue of the Journal of Clinical Pharmacology. The journal is published on behalf of the ACCP by SAGE.
Public Health

EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study

Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). For the dry eye clinical trial, EyeGate worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA. Over the past 30 years, Ora has been a pioneering force in the development of advanced research models across the field of ophthalmology. This Phase II single-center, randomized (105 patients), double-masked, placebo-controlled patient study evaluated the safety and efficacy of a corticosteroid solution (EGP-437) administered by the EyeGate® II Delivery System (at two dose levels) twice over a three-week period. Ora"s Controlled Adverse Environment (CAE) clinical research system, which simulates the acute environmental challenges regularly faced by DES patients, was used for this study. In the top-level analysis, investigators observed that EGP-437 significantly (p About Dry Eye Syndrome Dry Eye Syndrome (DES) is the most prevalent form of ocular discomfort and irritation, accounting for one in four patient visits to a general ophthalmologist. It is estimated that as many as 20 to 40 million Americans suffer from DES, including a significant number of patients who suffer from DES after Lasik surgery. Symptoms such as pain, light sensitivity, blurred vision, and irritation decrease the quality of life for patients and can ultimately lead to loss of function and blindness. The incidence of DES is increasing due to environmental factors, the aging population and the increasing prevalence of co-morbid diseases such as diabetes. There is no cure for DES, and the few treatment options currently available primarily provide temporary symptomatic relief. About Ora, Inc. Ora is the world"s leading independent ophthalmic drug and device development firm. Ora provides technology-based concept-to-market services and solutions that accelerate development timelines and improve the scientific quality of clinical research. Over the past 30 years, Ora has played a central role in the development and FDA approval of more than 30 ophthalmic products. For more information, please visit http://www.oraclinical.com. EyeGate Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009